Literature DB >> 7536489

Identification and characterization of a soluble c-kit receptor produced by human hematopoietic cell lines.

A M Turner1, L G Bennett, N L Lin, J Wypych, T D Bartley, R W Hunt, H L Atkins, K E Langley, V Parker, F Martin.   

Abstract

Stem cell factor (SCF) triggers cell growth by binding to cell surface c-kit receptors. Soluble forms of several cytokine receptors have been described and may play a role in the modulation of cytokine activity in vivo. For these reasons, we investigated whether human hematopoietic cells produce soluble c-kit receptors. The human leukemia cell lines OCIM1 and MO7e display approximately 80,000 and approximately 35,000 high-affinity cell surface c-kit receptors, respectively. Soluble c-kit receptors were detected by enzyme immunoassay in OCIM1 and MO7e culture supernatants. We determined the molecular weight and binding affinity of soluble c-kit receptor produced by OCIM1 cells, soluble c-kit receptor purified from human serum, and recombinant soluble c-kit receptor expressed in CHO cells. The three soluble c-kit receptors each have a molecular weight of 98 kD. Quantitative binding experiments with 125I-SCF indicate that the soluble c-kit receptors obtained from human serum or OCIM1 cells have binding affinities for SCF of approximately 200 to 300 pmol/L, in contrast to the recombinant form, which has a binding affinity of approximately 1.5 nmol/L. All three forms of the soluble c-kit receptor were able to compete with c-kit receptors on OCIM1 cells for 125I-SCF binding. Thus human hematopoietic cells can produce a soluble form of the c-kit receptor that retains high-affinity SCF binding activity. We speculate that the soluble c-kit receptor may bind SCF and function as a receptor antagonist in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7536489

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer.

Authors:  Philip J Saylor; Kevin R Kozak; Matthew R Smith; Marek A Ancukiewicz; Jason A Efstathiou; Anthony L Zietman; Rakesh K Jain; Dan G Duda
Journal:  Oncologist       Date:  2012-02-02

2.  A novel anti-c-Kit antibody-drug conjugate to treat wild-type and activating-mutant c-Kit-positive tumors.

Authors:  Jin-Ock Kim; Kwang-Hyeok Kim; Eun Ji Baek; Bomi Park; Min Kyung So; Byoung Joon Ko; Han-Jik Ko; Sang Gyu Park
Journal:  Mol Oncol       Date:  2021-08-29       Impact factor: 6.603

3.  Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer.

Authors:  Rachel M Ostroff; William L Bigbee; Wilbur Franklin; Larry Gold; Mike Mehan; York E Miller; Harvey I Pass; William N Rom; Jill M Siegfried; Alex Stewart; Jeffrey J Walker; Joel L Weissfeld; Stephen Williams; Dom Zichi; Edward N Brody
Journal:  PLoS One       Date:  2010-12-07       Impact factor: 3.240

4.  Lnk-dependent axis of SCF-cKit signal for osteogenesis in bone fracture healing.

Authors:  Tomoyuki Matsumoto; Masaaki Ii; Hiromi Nishimura; Taro Shoji; Yutaka Mifune; Atsuhiko Kawamoto; Ryosuke Kuroda; Tomoaki Fukui; Yohei Kawakami; Tomoya Kuroda; Sang Mo Kwon; Hiroto Iwasaki; Miki Horii; Ayumi Yokoyama; Akira Oyamada; Sang Yang Lee; Shinya Hayashi; Masahiro Kurosaka; Satoshi Takaki; Takayuki Asahara
Journal:  J Exp Med       Date:  2010-09-20       Impact factor: 14.307

5.  Significance of stem cell factor and soluble KIT in patients with systemic lupus erythematosus.

Authors:  T Kitoh; H Ishikawa; S Sawada; K Koshino; Y Tokano; H Hashimoto; S Nakagawa
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

6.  Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure.

Authors:  Samuel E Deprimo; Xin Huang; Martin E Blackstein; Christopher R Garrett; Charles S Harmon; Patrick Schöffski; Manisha H Shah; Jaap Verweij; Charles M Baum; George D Demetri
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531

7.  Cell-specific targeting of lentiviral vectors mediated by fusion proteins derived from Sindbis virus, vesicular stomatitis virus, or avian sarcoma/leukosis virus.

Authors:  Xian-Yang Zhang; Robert H Kutner; Agnieszka Bialkowska; Michael P Marino; William B Klimstra; Jakob Reiser
Journal:  Retrovirology       Date:  2010-01-25       Impact factor: 4.602

8.  Angiogenic and vasculogenic factors in the vitreous from patients with proliferative diabetic retinopathy.

Authors:  Ahmed M Abu El-Asrar; Mohd Imtiaz Nawaz; Dustan Kangave; Mohammed Mairaj Siddiquei; Karel Geboes
Journal:  J Diabetes Res       Date:  2013-03-10       Impact factor: 4.011

9.  Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.

Authors:  Samuel E Deprimo; Carlo L Bello; John Smeraglia; Charles M Baum; Dominic Spinella; Brian I Rini; M Dror Michaelson; Robert J Motzer
Journal:  J Transl Med       Date:  2007-07-02       Impact factor: 5.531

10.  Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer.

Authors:  Song Yi Bae; Ji-Young Hong; Hye-Jung Lee; Hyen Joo Park; Sang Kook Lee
Journal:  Oncotarget       Date:  2015-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.